A practical reference on peptide fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Usually, PMR only affects adults over the age of 50. The average age of a person who has PMR is about 70 years old, with the highest prevalence in those older than 70. Women are three times as likely to get PMR as men. People of Western and Northern European descent are more likely to get this disease. It is more likely to affect people of Northern European origin; Scandinavians are especially vulnerable. About 50% of people with temporal arteritis also have polymyalgia rheumatica.
=== Metabolic === Cachexia can also result from changes in metabolism. Tumors sometimes release molecules that break down fat and muscle, causing cachexia by making it harder for the body to keep up with energy needs. These molecules include lipid mobilizing factor, proteolysis-inducing factor, and mitochondrial uncoupling proteins. In addition, uncontrolled inflammation in people with cachexia increases the body's need for nutrients. The way the body uses nutrients is also changed in cachexia. People with cachexia can have loss of appetite, are less responsive to insulin, and can have increased fat breakdown, all of which make it difficult for the body to properly use food. This is especially true in people with cancer.
Zionism seeks to establish a home in Palestine for the Jewish people, secured under public law. The Second Aliyah (1904–1914) began after the Kishinev pogrom; some 40,000 Jews settled in Palestine, although nearly half of them left eventually. Both the first and second waves of migrants were mainly Orthodox Jews, although the Second Aliyah included socialist groups who established the kibbutz movement. Though the immigrants of the Second Aliyah largely sought to create communal agricultural settlements, the period saw the establishment of Tel Aviv as the first planned Jewish town in 1909. This period also saw the emergence of Jewish armed militias, the first being Bar-Giora, a guard founded in 1907. Two years later, the larger Hashomer organization was founded as its replacement. The Sykes–Picot Agreement of 16 May 1916 set aside the region of Palestine for "international administration" under British control. The first official use of the phrase "national home for the Jewish people" was in the Balfour Declaration. The phrase "national home" was intentionally used instead of "state" because of opposition to the Zionist program within the British Cabinet. The initial draft of the declaration referred to the principle "that Palestine should be reconstituted as the National Home of the Jewish people."
== Medical Applications/Pharmacology == Hyperglycemia, a side effect caused by diabetes, combines with oxidative stress to create advanced glycation end-products (AGEs) that can lead to diabetic retinopathy (DR), age related macular degeneration (AMD) and cataracts. Enhancing the glyoxalase system has been shown to delay accumulation of AGEs and associated retinal damage in animals that consume higher glycemic index diets. This was corroborated upon over-expression of GLO1, which in C. elegans reduced basal MG concentration, prevented mitochondrial protein modification and enhanced lifespan. Similarly, in mice, GLO1 over-expression reduced baseline MG concentrations in the brain. In diabetic mice, it prevented diabetes-induced increases in MG modification of glomerular proteins, reduced oxidative stress, and prevented development of diabetic kidney pathology, despite unchanged levels of hyperglycemia. Western diets, typically high in glycemic index, exacerbate AGE accumulation and amplify aging-related damage. Enhancing the glyoxalase system may offer a promising therapeutic strategy to prevent the onset and progression of AGEs-related diseases. Oxidative stress can lead to worsening neurological diseases such as Alzheimer's, Parkinson's, and Autism Spectrum Disorder. Flavonoids, a type of antioxidant that combats oxidative stress in the body, has been found to help decrease the production of radical oxygen species (ROS) mostly by preventing the formation of free radicals, additionally they partially enhance the transcription of glyoxalase.
Sources: en.wikipedia.org
1911 – Marie Sklodowska-Curie – discovery of radium & polonium 1935 – Irène Joliot-Curie – artificial radioactivity 1964 – Dorothy Crowfoot Hodgkin – protein crystallography 2009 – Ada E. Yonath – structure & function of the ribosome 2018 – Frances Arnold – directed evolution to engineer enzymes 2020 – Emmanuelle Charpentier and Jennifer Doudna – for CRISPR gene editing 2022 - Carolyn R. Bertozzi - for bioorthogonal chemistry Eight women have won the Nobel Prize in Chemistry (listed above), awarded annually since 1901 by the Royal Swedish Academy of Sciences. Marie Curie was the first woman to receive the prize in 1911, which was her second Nobel Prize (she also won the prize in physics in 1903, along with Pierre Curie and Henri Becquerel – making her the only woman to be award two Nobel prizes). Her prize in chemistry was for her "discovery of the elements radium and polonium, by the isolation of radium and the study of the nature and compounds of this remarkable element." Irene Joliot-Curie, Marie's daughter, became the second woman to be awarded this prize in 1935 for her discovery of artificial radioactivity. Dorothy Hodgkin won the prize in 1964 for the development of protein crystallography. Among her significant discoveries are the structures of penicillin and vitamin B12. Forty five years later, Ada Yonath shared the prize with Venkatraman Ramakrishnan and Thomas A. Steitz for the study of the structure and function of the ribosome.
In October 2020, Nick Tarabay joined the cast as a series regular as Eclipso while Jonathan Cake was cast as Shade and Ysa Penarejo was cast in an undisclosed role in recurring capacities for the second season (later revealed to be Jennifer-Lynn Hayden / Jade, the daughter of Green Lantern), while Jim Gaffigan was cast as the voice of Thunderbolt. The following month, Alkoya Brunson was cast in a recurring role as Jakeem Thunder. In February 2021, John Wesley Shipp was revealed to be reprising his role as Jay Garrick from The Flash, albeit as an alternate version. Alex Collins replaced Thomas as Doctor Mid-Nite for the second season. Hopkins and Osmanski were promoted to series regulars for the third season in August 2021, following their recurring roles in the first season and guest appearance in the second. McHale was also promoted to a series regular in October for the third season following his guest appearances in the first two seasons. In March 2022, Tim Gabriel was cast as Todd Rice / Obsidian. In May, Seth Green joined the cast in recasting to succeed Gaffigan who voiced Thunderbolt last season. The third season trailer confirmed the return of Eric Goins as Steven Sharpe / Gambler, who appeared in the first but was absent from the second.
== Sources of exposure == Aflatoxin B1 is mostly found in contaminated food and humans are exposed to aflatoxin B1 almost entirely through their diet. Occupational exposure to aflatoxin B1 has also been reported in swine and poultry production. While aflatoxin B1 contamination is common in many staple foods, its production is maximized in foods stored in hot, humid climates. Exposure is therefore most common in Southeast Asia, South America, and Sub-Saharan Africa.
In situ technology of phytoremediation could also be utilized, even though perchlorate phytoremediation mechanism is not fully founded yet. Bioremediation using perchlorate-reducing bacteria, which reduce perchlorate ions to harmless chloride, has also been proposed.
==== Menstrual bleeding ==== Tranexamic acid is sometimes used to treat heavy menstrual bleeding. When taken by mouth it both safely and effectively treats regularly occurring heavy menstrual bleeding and improves quality of life. Another study demonstrated that the dose does not need to be adjusted in females who are between ages 12 and 16. In a 10-year study, tranexamic acid and other oral medicines (mefenamic acid) were found to be as effective as the levonorgestrel intrauterine coil; the same proportion of women had not had surgery for heavy bleeding and had similar improvements in their quality of life.
Sources: en.wikipedia.org
Heseltine spent nine weeks in the ranks as a Guardsman before being sent for three months of officer training at Mons Officer Cadet School, Aldershot, alongside men from other regiments. He was a capable cadet, reaching the rank of Junior Under-Officer and graduating with an A-Grade, but he was not awarded the Sword of Honour or promoted to the rank of Senior Under-Officer, as it was felt his age had given him an unfair advantage over younger cadets. Throughout his training he had been troubled by an old ankle sprain, but he declined the offer of a medical discharge. He was commissioned as a second lieutenant on 11 June 1959. Heseltine was granted leave to contest the general election in October that year; according to Ian Josephs this had been his plan from the start. Afterward he applied on business grounds for exemption from return to the Army, in part because of difficulties caused by an employee's embezzlement, and partly including the need to sort out his late father's affairs, and was exempted from his remaining sixteen months of service. During the 1980s his habit of wearing a Guards regimental tie, sometimes incorrectly knotted with a red stripe on the neck, was the subject of much acerbic comment from military figures and from older MPs with distinguished war records. Crick estimated that he must have worn the tie on more days than he actually served in the Guards.
Asian citrus psyllid on the UF / IFAS Featured Creatures Web site Species Profile – Citrus Greening and Species Profile – Asian Citrus Psyllid, National Invasive Species Information Center, National Agricultural Library. Lists general information and resources for citrus greening and the Asian citrus psyllid. CISR: Huanglongbing/Citrus Greening Center for Invasive Species Research page on Huanglongbing and Citrus Greening
=== Sex === Differences in male and female skeletal anatomy are used by bioarchaeologists to determine the biological sex of human skeletons. Humans are sexually dimorphic, although overlap in body shape and sexual characteristics is possible. Not all skeletons can be assigned a sex, and some may be wrongly identified. Biological males and biological females differ most in the skull and pelvis; bioarchaeologists focus on these body parts, although other body parts can be used. The female pelvis is generally broader than the male pelvis, and the angle between the two inferior pubic rami (the sub-pubic angle) is wider and more U-shaped, while the sub-pubic angle of the male is more V-shaped and less than 90 degrees. In general, the male skeleton is more robust than the female skeleton because of male's greater muscles mass. Male skeletons generally have more pronounced brow ridges, nuchal crests, and mastoid processes. Skeletal size and robustness are influenced by nutrition and activity levels. Pelvic and cranial features are considered to be more reliable indicators of biological sex. Sexing skeletons of young people who have not completed puberty is more difficult and problematic, because the body has not fully developed. Bioarchaeological sexing of skeletons is not error-proof. Recording errors and re-arranging of human remains may play a part in such misidentification.
As a result of this change tropical cyclones are 50% less likely to make landfall on Queensland, while the risk of a tropical cyclone is elevated for island nations like Niue, French Polynesia, Tonga, Tuvalu, and the Cook Islands.
== Overview == Radionuclides occur naturally and are artificially produced in nuclear reactors, cyclotrons, particle accelerators or radionuclide generators. There are 735 known radionuclides with half-lives longer than an hour (see list of nuclides); 35 of those are primordial radionuclides whose presence on Earth has persisted from its formation, and another 62 are detectable in nature, continuously produced either as daughter products of primordial radionuclides or by cosmic radiation. More than 2400 radionuclides have half-lives less than 60 minutes. Most of those are only produced artificially, and have very short half-lives. For comparison, there are 251 stable nuclides.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.